Scholarlink

<p>With high rates of occurrence, recurrence, and mortality, ovarian cancer(OC) is among the most prevalent malignant neoplasms of the female reproductive system, which frequently result in a poor prognosis. The limited efficacy of early diagnosis and screening measures results in 75% of patients being diagnosed at an advanced stage. Despite the achievements of conventional therapeutic modalities, these therapies continue to experience challenges, including the occurrence of relapses and the development of drugs resistance.Recent advancements in precision medicine have identified the T-cell receptor (TCR) as a pivotal biomarker for both early ovarian cancer diagnosis and immunotherapy, given its central role in antigen recognition. This paper elaborates on the structure and function of the T-cell receptor, TCR immunohistochemistry repertoire and detection technology, TCR repertoire application in disease prediction, and the TCR-based immunotherapy strategy (known as TCR-T-cell therapy), along with its application and challenge in ovarian cancer.</p> Graphical abstract <p>From TCR Biology to Clinical Applications</p> <p>Figure abbreviation: ITAM: immunoreceptor tyrosine-based activation motif; ITK: IL-2-inducible tyrosine kinase; LATs: linkers for the activation of T cells; LCK: leukocyte-specific tyrosine kinase; MAPK: mitogen-activated protein kinase; NFAT: nuclear factor of activated T cells; NF-κB: nuclear factor-kappa B; PKC：protein kinase C; MHC: major histocompatibility complex; SLP-76: SH2-domain-containing leukocyte protein of 76 kDa; TCR: T-cell receptor; TAAs: tumor-associated antigens; TSAs: tumor-specific antigens; VEGF: vascular endothelial growth factor.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

T-cell receptor therapy in ovarian cancer: concepts and challenges

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月13日

查看全文
  • Xiaohan Wang,
  • Zhuoyao Li,
  • Mengwen Zhang,
  • Yunhe Yu,
  • Weihua Tong

摘要

With high rates of occurrence, recurrence, and mortality, ovarian cancer(OC) is among the most prevalent malignant neoplasms of the female reproductive system, which frequently result in a poor prognosis. The limited efficacy of early diagnosis and screening measures results in 75% of patients being diagnosed at an advanced stage. Despite the achievements of conventional therapeutic modalities, these therapies continue to experience challenges, including the occurrence of relapses and the development of drugs resistance.Recent advancements in precision medicine have identified the T-cell receptor (TCR) as a pivotal biomarker for both early ovarian cancer diagnosis and immunotherapy, given its central role in antigen recognition. This paper elaborates on the structure and function of the T-cell receptor, TCR immunohistochemistry repertoire and detection technology, TCR repertoire application in disease prediction, and the TCR-based immunotherapy strategy (known as TCR-T-cell therapy), along with its application and challenge in ovarian cancer.

Graphical abstract

From TCR Biology to Clinical Applications

Figure abbreviation: ITAM: immunoreceptor tyrosine-based activation motif; ITK: IL-2-inducible tyrosine kinase; LATs: linkers for the activation of T cells; LCK: leukocyte-specific tyrosine kinase; MAPK: mitogen-activated protein kinase; NFAT: nuclear factor of activated T cells; NF-κB: nuclear factor-kappa B; PKC：protein kinase C; MHC: major histocompatibility complex; SLP-76: SH2-domain-containing leukocyte protein of 76 kDa; TCR: T-cell receptor; TAAs: tumor-associated antigens; TSAs: tumor-specific antigens; VEGF: vascular endothelial growth factor.